Pharma Sector Playbook
Indian pharma companies operate across three business models — often within the same company. Understanding the mix is critical for analysis. | Segment | Exa...
How pharma companies work
Indian pharma companies operate across three business models — often within the same company. Understanding the mix is critical for analysis.
Business segments
| Segment | Examples | Margin Profile | Growth Driver |
|---|---|---|---|
| API (Active Pharma Ingredient) | Divi's Labs, Laurus | Gross: 50–60% | China+1, capacity expansion |
| Generic Formulations (India) | Sun Pharma, Cipla, Dr Reddy's | Gross: 65–75% | Chronic therapies, penetration |
| Generic Formulations (US) | Same + Aurobindo, Glenmark | Gross: 50–60% | ANDA filings, first-to-files, price erosion |
| CRAMS/CDMO | Syngene, Divi's Labs | Gross: 55–65% | Outsourcing trend, patent cliffs |
| Biosimilars | Biocon | Gross: 45–55% | Patent expiry of biologics |
🗣️
"Pharma mein asli samajhna yeh hai — API bechte ho ya formulation? India mein? Ya US mein? Sab ka margin alag."
The 6 metrics that define pharma
1. Revenue Mix (India vs US vs Rest of World)
| Geography | Characteristics |
|---|---|
| India domestic | Branded generics, high margin, competitive but sticky |
| US generics | ANDA-driven, price erosion 5–10% annually, commodity-like |
| Europe | Tender-based, low margins, steady volume |
| Emerging markets | Growing, regulatory hurdles, currency risk |
| CRAMS/API exports | B2B, relationship-driven, capacity-dependent |
US concentration risk
Companies with > 40% revenue from US generics face structural price erosion. USFDA scrutiny adds regulatory risk. Diversification is key.
2. R&D Spend (% of Revenue)
R&D % = (R&D Expense) / Revenue × 100
| R&D Range | Interpretation |
|---|---|
| 2–4% | Minimal innovation, commodity generic player |
| 5–8% | Active pipeline, diversified filings |
| 8–12% | Innovation-led (biosimilars, specialty drugs, NCEs) |
| > 12% | High-risk R&D bets (early-stage drug discovery) |
3. ANDA Pipeline (US Generics)
ANDA = Abbreviated New Drug Application (US FDA approval for generics).
| Metric | What to track |
|---|---|
| Total ANDAs filed | Size of opportunity pipeline |
| Pending approvals | Near-term revenue potential |
| First-to-file (FTF) | 180-day exclusivity = highest margin opportunities |
| Para-IV challenges | Patent challenge filings — high risk, high reward |
4. Gross Margin by Segment
| Segment | Healthy Gross Margin |
|---|---|
| India branded generics | 65–75% |
| US generics | 50–60% (declining with price erosion) |
| API | 50–60% |
| CDMO | 55–65% |
Mix shift drives margin
A shift from US generics (50%) to India domestic (70%) improves blended margins dramatically — even without operational changes.
5. USFDA Compliance Status
USFDA inspects Indian manufacturing plants regularly. Outcomes:
| Status | Impact |
|---|---|
| EIR (Establishment Inspection Report) | All clear — plant approved |
| Form 483 | Observations — minor to serious issues flagged |
| Warning Letter | Serious violations — new ANDAs from that plant suspended |
| Import Alert | Products from that plant banned from US market |
USFDA warning letters
A warning letter can freeze new product launches from the affected plant for 12–24 months. It directly hits US revenue growth.
6. ROCE / Capital Efficiency
| Company Type | Expected ROCE |
|---|---|
| Asset-light (India branded + CRAMS) | > 20% |
| Integrated (API + Formulations) | 15–20% |
| Capex-heavy API expansion | 10–15% (improving post-expansion) |
Red flags for pharma stocks
Pharma red flags
- USFDA Warning Letter — US revenue at risk, no new product approvals
- US revenue declining 10%+ without pipeline offset — price erosion without new launches
- R&D spend declining or < 3% of revenue — not investing in future products
- Single-product/single-geography dependence — > 30% from one drug or market
- Approval delays stacking up — ANDA backlog growing, not converting to revenue
- Debt taken for large acquisitions — risky in a price-erosion market
- Consistent quality issues — repeated Form 483 observations across plants
- Branded generics market share loss in India — field force inefficiency
Valuing pharma companies
| Business Type | Preferred Metric | Typical Range |
|---|---|---|
| India domestic focus | PE | 25–40x |
| US generics heavy | PE or EV/EBITDA | 12–20x (price erosion discount) |
| CDMO/CRAMS pure-play | EV/EBITDA | 20–35x (growth premium) |
| API manufacturer | PE | 15–25x |
| Diversified (Sun Pharma type) | PE + SOTP | 25–35x |
Sum-of-the-Parts (SOTP) is often best for large pharma companies:
- Value India business at domestic peer multiples
- Value US business at US generic peer multiples
- Value specialty/innovative pipeline separately (option value)
Case study: Sun Pharma vs Dr Reddy's vs Divi's Labs
| Metric | Sun Pharma | Dr Reddy's | Divi's Labs |
|---|---|---|---|
| Revenue (₹ Cr) | ~48,000 | ~27,000 | ~8,500 |
| India Revenue % | 35% | 25% | 5% |
| US Revenue % | 30% | 45% | 10% |
| API/CDMO % | 5% | 10% | 85% |
| R&D % Revenue | 7% | 12% | 3% |
| EBITDA Margin | 28% | 25% | 35% |
| ROCE | 14% | 12% | 22% |
| PE | 35x | 22x | 45x |
Sun Pharma: Highest India presence + specialty business (Ilumya, Absorica) → premium justified. Dr Reddy's: US heavy + high R&D → valued lower due to price erosion, but pipeline is strong. Divi's Labs: API/CDMO pure-play → highest margins, but API is cyclical. PE reflects outsourcing tailwind.
🏢 Apply: See it on InvestingSamjho
Pharma analysis exercise
- Compare 3 pharma companies: 1 India-focused, 1 US-focused, 1 API/CDMO
- Check revenue mix by geography over 3 years
- Compare EBITDA margins and ROCE — how does the mix drive returns?
- Check USFDA compliance status from latest annual report
- Calculate R&D intensity — which company is investing most in the future?
Summary
Pharma investing requires understanding the revenue mix (India vs US vs API), pipeline quality (ANDA filings, FTFs), and regulatory risk (USFDA compliance). Never invest in a pharma company without knowing which plants serve which markets.
1. Pharma — Business Models
What you will learn
- The 4 pharma business models and how they differ
- API vs Formulations — the value chain basics
- CRAMS/CDMO — the outsourcing megatrend
- Why most Indian pharma companies are multi-model hybrids
The pharma value chain
Indian pharma operates mainly in B, C, and D — not drug discovery (that's Big Pharma like Pfizer, Roche). India's advantage is low-cost manufacturing at scale.
Model 1: API manufacturing
API = Active Pharmaceutical Ingredient — the molecule that provides the therapeutic effect. Everything else in a tablet (binders, fillers, coating) are excipients.
| Characteristic | Detail |
|---|---|
| What they make | Raw drug molecules (e.g., Ibuprofen API, Metformin API) |
| Who buys | Other pharma companies (B2B) |
| Margin profile | Gross: 50-60%, EBITDA: 25-35% |
| Key advantage | Scale, process chemistry, cost efficiency |
| Key risk | Cyclicality (demand-supply imbalance), China competition |
Why API matters for India
India was historically dependent on China for 60-70% of key starting materials (KSMs) and intermediates. Post-COVID, the "China+1" strategy led global pharma to diversify supply chains to India.
| Example Companies | Focus |
|---|---|
| Divi's Laboratories | Custom synthesis + generic APIs (major global supplier) |
| Laurus Labs | API backward integration, ARV APIs, oncology |
| Shilpa Medicare | Oncology APIs |
| Solara Active Pharma | Ibuprofen, Ranitidine APIs (volume plays) |
API operating model
| Revenue Driver | What to Track |
|---|---|
| Capacity utilisation | Plants running at 70-80% = healthy; > 85% = expansion needed |
| Product basket diversity | > 20 APIs = diversified; < 5 = concentration risk |
| Customer concentration | Top-3 customers < 30% of revenue = healthy |
| Pricing trend | API prices are cyclical — check if current cycle is up or down |
Model 2: Generic formulations
Generic = same molecule as the innovator drug (whose patent has expired), manufactured and sold at a fraction of the price.
India domestic formulations
India's pharma market is a branded generic market — same molecule, but sold under a brand name. This is unlike the US, where generics are interchangeable commodities.
| Characteristic | Detail |
|---|---|
| Market size | ~₹2 lakh crore (growing 8-10% annually) |
| Margin profile | Gross: 65-75%, EBITDA: 22-30% |
| Competitive moat | Brand recognition, doctor prescriptions, field force reach |
| Key driver | Chronic therapy share (diabetes, cardiac, neuro) growing |
Chronic vs Acute therapies:
| Type | Examples | Revenue Quality |
|---|---|---|
| Chronic | Diabetes, cardiac, CNS, respiratory | Recurring prescriptions, sticky revenue |
| Acute | Antibiotics, pain, fever, cough | Seasonal, one-off prescriptions |
Chronic > Acute for long-term investing
Companies with > 50% chronic therapy revenue have more predictable, growing revenue. Chronic therapy patients take medicines for years — acute is episodic. Check therapy mix in annual reports.
US generic formulations
The US generic market works completely differently from India:
| US Market Feature | Implication |
|---|---|
| No brand loyalty | Pharmacy substitutes cheapest generic automatically |
| 5-10% annual price erosion | Revenue declines unless new products launched constantly |
| ANDA approval required | USFDA regulated — expensive, time-consuming ($2-5M per ANDA) |
| Oligopolistic in some molecules | First 2-3 filers capture most volume |
US generic revenue formula
US Revenue = Σ (Approved ANDAs × Market Share × Price After Erosion)
A company needs a pipeline factory — constantly filing new ANDAs as old products face price erosion. If new launches slow down, US revenue structurally declines.
Model 3: CRAMS / CDMO
CRAMS = Contract Research and Manufacturing Services CDMO = Contract Development and Manufacturing Organization
These companies don't own the drug — they manufacture for global innovators (Pfizer, Sanofi, etc.) on contract.
| Characteristic | Detail |
|---|---|
| Revenue model | Cost-plus or fixed-fee manufacturing contracts |
| Contract duration | 3-7 years (sticky, long-term) |
| Margin profile | Gross: 55-65%, EBITDA: 28-40% |
| Key advantage | Process chemistry skills, lower cost, regulatory compliance |
| Growth driver | Global outsourcing trend, patent cliff (biologics going off patent) |
CDMO revenue characteristics
| Feature | Good | Bad |
|---|---|---|
| Contract duration | Multi-year (3-7 years) | Short-term (<1 year) = project-based risk |
| Client base | Top-20 global pharma | Single client > 40% revenue |
| Revenue visibility | Order book disclosed | No order book disclosure |
| Capacity utilisation | 70-85% | < 60% or > 90% |
Key CDMO companies: Syngene International, Divi's Labs (custom synthesis division), Laurus Labs, Piramal Pharma, Suven Pharma.
Model 4: Biosimilars
Biosimilars = copies of biologic drugs (made from living cells, not chemical synthesis). Much harder to manufacture than generic small molecules.
| Biosimilars vs Generics | Key Difference |
|---|---|
| Development cost | $50-200M (biosimilar) vs $2-5M (generic ANDA) |
| Time to market | 5-8 years vs 2-4 years |
| Price discount | 20-35% vs 70-90% off innovator |
| Interchangeability | Not automatic — requires additional testing |
| Market opportunity | $100B+ of biologics losing patent protection by 2030 |
Key Indian player: Biocon Biologics (insulin biosimilars, oncology biosimilars in US/Europe).
The multi-model hybrid — how to read a pharma company
Most Indian pharma companies operate across 2-3 models simultaneously:
| Company | API | India Formuln | US Generics | CDMO | Biosimilars |
|---|---|---|---|---|---|
| Sun Pharma | ✗ | ✅ (35%) | ✅ (30%) | ✗ | ✗ |
| Dr Reddy's | ✅ (10%) | ✅ (25%) | ✅ (45%) | ✗ | ✅ (small) |
| Cipla | ✗ | ✅ (40%) | ✅ (25%) | ✗ | ✗ |
| Divi's Labs | ✅ (50%) | ✗ | ✗ | ✅ (35%) | ✗ |
| Biocon | ✅ (15%) | ✗ | ✗ | ✅ (25%) | ✅ (40%) |
Key insight: The revenue mix determines the margin profile, growth trajectory, and risk profile. India-heavy = stable, high-margin. US-heavy = growth dependent on pipeline, price erosion risk. CDMO = high visibility but capacity-dependent.
✅ Checklist
- ○I can identify which business model(s) a pharma company operates in
- ○I understand API (B2B, cyclical) vs Formulations (branded in India, commodity in US)
- ○I know CDMO is the outsourcing megatrend — long contracts, sticky revenue
- ○I check chronic vs acute therapy mix for India-focused companies
Key takeaway
Indian pharma has 4 business models — API, generic formulations (India & US), CRAMS/CDMO, and biosimilars — and most large companies are hybrids. The revenue mix defines everything: India domestic = stable + high-margin, US generics = pipeline-dependent + price erosion risk, CDMO = sticky + growing, biosimilars = high-risk/high-reward. Always start by understanding the mix before looking at financials.
2. Pharma — Revenue Mix & Geography
How pharma revenue characteristics differ by geography India domestic — branded generics, field force, chronic therapy shift US generics — the ANDA treadmill...
Full sector playbook is a Pro feature
Sign up to continue learning — unlock the full path, in-depth lessons, projects, and every tool on the platform.
3. Pharma — Pipeline & R&D
ANDA pipeline economics — filings, approvals, and the FTF jackpot R&D intensity and what it tells you about future growth Patent cliffs — the biggest opportu...
Full sector playbook is a Pro feature
Sign up to continue learning — unlock the full path, in-depth lessons, projects, and every tool on the platform.
4. Pharma — USFDA & Regulatory Risk
The USFDA inspection framework and what each outcome means How Warning Letters and Import Alerts destroy value Quality risk assessment — what to look for The...
Full sector playbook is a Pro feature
Sign up to continue learning — unlock the full path, in-depth lessons, projects, and every tool on the platform.
5. Pharma — Valuation Framework
PE vs EV/EBITDA — when to use which for pharma SumoftheParts (SOTP) — valuing pharma conglomerates Valuation benchmarks by business type Sun Pharma vs Dr Red...
Full sector playbook is a Pro feature
Sign up to continue learning — unlock the full path, in-depth lessons, projects, and every tool on the platform.